/PRNewswire/ RhythmScience, a leader in cardiac data management and services, today announced the formation of its Medical Advisory Board (MAB). Comprised.
/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the.
- ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types - - Company to Host Investor Webcast on June
Adjuvant Pembro Success in Early Melanoma Raises Questions medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.